Palatin Technologies Inc
LSE:0KF3

Watchlist Manager
Palatin Technologies Inc Logo
Palatin Technologies Inc
LSE:0KF3
Watchlist
Price: 0.1095 USD 9.39% Market Closed
Market Cap: 3B USD

Net Margin
Palatin Technologies Inc

-7 700.6%
Current
-2 051%
Average
-6.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-7 700.6%
=
Net Income
-27m
/
Revenue
350k

Net Margin Across Competitors

Palatin Technologies Inc
Glance View

Market Cap
3B USD
Industry
Biotechnology

Palatin Technologies Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies to address unmet medical needs in various health conditions, particularly in women's health and sexual dysfunction. The company is primarily known for its lead product candidate, Vyleesi (bremelanotide injection), which was approved by the FDA for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). This groundbreaking therapy offers a novel approach to a condition that has traditionally been underserved, highlighting Palatin’s commitment to improving quality of life for its patients. With a robust pipeline of other potential treatments, the company is positioning itself to be a significant player in the biotech sector. Investors will find Palatin appealing not only for its unique product offerings but also for its strategic partnerships and collaborations that enhance its research capabilities and market reach. The company has established relationships with key healthcare organizations, enabling it to conduct pivotal clinical trials and expand its product visibility. Additionally, leadership at Palatin utilizes a disciplined, value-investing approach, ensuring that resources are allocated wisely towards projects with solid scientific backing and commercial potential. As the company advances its portfolio, it aims to create long-term shareholder value while addressing critical areas of health, making it a compelling opportunity for those looking to invest in the future of biopharmaceutical innovations.

0KF3 Intrinsic Value
0.0541 USD
Overvaluation 51%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-7 700.6%
=
Net Income
-27m
/
Revenue
350k
What is the Net Margin of Palatin Technologies Inc?

Based on Palatin Technologies Inc's most recent financial statements, the company has Net Margin of -7 700.6%.

Back to Top